Optiscan kicks off GI study in Germany with first imaging prototype
Posted: 5 February 2025 Optiscan has been featured in Stockhead, The Australian, and 11 News Corp mastheads following the announcement of its pre-clinical gastrointestinal (GI) study in Germany. The piece explores how Optiscan’s first flexible GI imaging prototype…
Alterity Therapeutics Announces Funding to Accelerate ATH434 Clinical and Business Development Activities
Posted: 5 February 2025 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it raised capital in the U.S. to accelerate clinical development…
Phrenix secures major funding boost from US and Australian venture capital firms to advance new therapeutics for psychiatric disorders
Posted: 5 February 2025 Phrenix Therapeutics, a cutting-edge biotech company focused on next-generation medicines for psychiatric and neurological disorders, has secured significant seed investment from specialist biotech venture capital firms Curie.Bio (US) and Brandon Capital (Australia). Founded in 2022, Phrenix Therapeutics is…
IMPROVING CANCER OUTCOMES BY BACKING OUR RESEARCHERS
Posted: 5 February 2025 The Allan Labor Government is backing Victoria’s world-class cancer researchers, delivering $2.7 million to improve cancer outcomes and save lives across the state. Marking World Cancer Day, Minister for Health Mary-Anne Thomas today announced…
$11 million to build and grow on Australian research in climate change and health
Posted: 31 January 2025 A TCR is a one-time request for grant applications to address a specific health issue where there is significant research knowledge gap or unmet need. TCRs are designed to stimulate research or build research…
Blood immune cells could hold key to showing disease progression in Parkinson’s
Posted: 31 January 2025 A new discovery in blood immune cells has put researchers one step closer to identifying a blood biomarker that would allow doctors to personalise treatments for Parkinson’s disease. In a multi-disciplinary effort, researchers from the…
Researchers discover how cigarette smoke impairs critical lung immune cells
Posted: 31 January 2025 Cigarette smoking is widespread and deadly, yet our understanding of how cigarette smoke actually causes serious respiratory illnesses in incomplete, which has severely hampered the development of effective treatments. In the Journal of Experimental Medicine (JEM)…
Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy
Posted: 31 January 2025 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced positive topline results from the ATH434-201 randomized, double-blind, placebo-controlled Phase…
New tool can detect fast-spreading SARS-COV-2 variants before they take off
Posted: 31 January 2025 Researchers have developed a powerful tool that can detect variants of SARS-CoV-2 with high transmission potential before they become widespread. This approach could significantly support public health efforts to control outbreaks and help identify…
Professor Tony Haymet Australia’s new Chief Scientist
Posted: 29 January 2025 A world-leading oceanographer, chemist and entrepreneur has been appointed Australia’s next Chief Scientist. Emeritus Professor Tony Haymet will become Australia’s tenth Chief Scientist, taking over from Dr Cathy Foley who recently finished her term.…
Solving Critical Neonatal Challenges with a Design-Led Solution that Reduces Risks and Saves Lives
Posted: 28 January D+I Part of Capgemini (D+I) for Navi Medical Technologies Design can change lives. And when those lives are tiny, the impact is even greater. The Head of D+I Part of Capgemini Melbourne (D+I) – Rod Wiebenga has…
DoD to conduct Paid CT:VQ Pilot Ahead of FDA Submission
Posted: 28 January 2025 4DMedical has won a contract with the United States Department of Defense (DoD) to pilot its CT Ventilation-Perfusion (CT:VQ™) technology to assess lung health in a fixed cohort of active duty personnel. This contract…
